Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
China Resources Pharmaceutical Group Limited has announced a delay in sending to shareholders a circular related to its sales framework agreement for 2026–2028 with China Resources Healthcare Group Limited. The circular, which will include details of the agreement, proposed annual caps, independent board and financial adviser opinions, and notice of an extraordinary general meeting, was originally expected within 15 business days of a 16 December 2025 announcement but will now be dispatched on or before 15 January 2026 to allow more time to prepare and finalise the required information under Hong Kong listing rules.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, incorporated in Hong Kong and listed on the Stock Exchange of Hong Kong, operates in the pharmaceutical industry and is part of the broader China Resources conglomerate. The company’s business spans the manufacturing, distribution and sales of pharmaceutical products and related healthcare services across mainland China, serving hospitals, healthcare institutions and retail channels.
Average Trading Volume: 13,251,940
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.03B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.